Cyteir Therapeutics, Inc.
CYT · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $100 | $100 | $308 | $326 |
| Gross Profit | -$100 | -$100 | -$308 | -$326 |
| % Margin | – | – | – | – |
| R&D Expenses | $2,676 | $5,403 | $9,312 | $7,470 |
| G&A Expenses | $2,495 | $4,204 | $4,110 | $2,583 |
| SG&A Expenses | $2,495 | $4,204 | $4,110 | $2,583 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $1,260 |
| Operating Expenses | $5,171 | $9,607 | $13,422 | $10,053 |
| Operating Income | -$5,171 | -$9,607 | -$13,422 | -$10,053 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1,639 | $1,203 | $936 | $1,260 |
| Pre-Tax Income | -$3,532 | -$8,404 | -$12,486 | -$8,793 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3,532 | -$8,404 | -$11,550 | -$7,398 |
| % Margin | – | – | – | – |
| EPS | -0.098 | -0.24 | -0.32 | -0.21 |
| % Growth | 59.2% | 25% | -52.4% | – |
| EPS Diluted | -0.098 | -0.24 | -0.32 | -0.21 |
| Weighted Avg Shares Out | 36,030 | 35,744 | 35,588 | 35,376 |
| Weighted Avg Shares Out Dil | 36,030 | 35,744 | 35,588 | 35,376 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,639 | $1,203 | $1,543 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $110 | $108 | $607 | $170 |
| EBITDA | -$5,061 | -$9,499 | -$13,422 | -$8,658 |
| % Margin | – | – | – | – |